72 related articles for article (PubMed ID: 24129407)
21. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.
Vande Casteele N; Khanna R; Levesque BG; Stitt L; Zou GY; Singh S; Lockton S; Hauenstein S; Ohrmund L; Greenberg GR; Rutgeerts PJ; Gils A; Sandborn WJ; Vermeire S; Feagan BG
Gut; 2015 Oct; 64(10):1539-45. PubMed ID: 25336114
[TBL] [Abstract][Full Text] [Related]
22. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis.
Arias MT; Vande Casteele N; Vermeire S; de Buck van Overstraeten A; Billiet T; Baert F; Wolthuis A; Van Assche G; Noman M; Hoffman I; D'Hoore A; Gils A; Rutgeerts P; Ferrante M
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):531-8. PubMed ID: 25117777
[TBL] [Abstract][Full Text] [Related]
23. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.
Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Nardone OM; De Vitis I; Papa A; Rapaccini GL; Guidi L
Inflamm Bowel Dis; 2014 Aug; 20(8):1368-74. PubMed ID: 24983979
[TBL] [Abstract][Full Text] [Related]
24. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies.
Beigel F; Deml M; Schnitzler F; Breiteneicher S; Göke B; Ochsenkühn T; Brand S
PLoS One; 2014; 9(6):e99293. PubMed ID: 24932476
[TBL] [Abstract][Full Text] [Related]
25. Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy.
Farkas K; Lakatos PL; Szűcs M; Pallagi-Kunstár É; Bálint A; Nagy F; Szepes Z; Vass N; Kiss LS; Wittmann T; Molnár T
World J Gastroenterol; 2014 Mar; 20(11):2995-3001. PubMed ID: 24659890
[TBL] [Abstract][Full Text] [Related]
26. National Trends in Hospitalization, Surgical Resection, and Comorbidities in Pediatric Inflammatory Bowel Disease in the United States, 2002-2015.
Ihekweazu FD; Dongarwar D; Salihu HM; Kellermayer R
Int J MCH AIDS; 2022; 11(1):e522. PubMed ID: 35601678
[TBL] [Abstract][Full Text] [Related]
27. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis.
Ferretti F; Cannatelli R; Monico MC; Maconi G; Ardizzone S
J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566428
[TBL] [Abstract][Full Text] [Related]
28. Progression to colectomy in the era of biologics: A single center experience with pediatric ulcerative colitis.
Ihekweazu FD; Fofanova T; Palacios R; Ajjarapu A; Karam L; Vogel AM; Rodriguez JR; Kellermayer R
J Pediatr Surg; 2020 Sep; 55(9):1815-1823. PubMed ID: 32087936
[TBL] [Abstract][Full Text] [Related]
29. Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis.
Nguyen NH; Kurnool S; Dulai PS; Boland BS; Sandborn WJ; Singh S
Inflamm Bowel Dis; 2020 Aug; 26(9):1429-1435. PubMed ID: 31748806
[TBL] [Abstract][Full Text] [Related]
30. The Role of Early Biologic Therapy in Inflammatory Bowel Disease.
Berg DR; Colombel JF; Ungaro R
Inflamm Bowel Dis; 2019 Nov; 25(12):1896-1905. PubMed ID: 30934053
[TBL] [Abstract][Full Text] [Related]
31. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817
[TBL] [Abstract][Full Text] [Related]
32. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience.
Laharie D; Filippi J; Roblin X; Nancey S; Chevaux JB; Hébuterne X; Flourié B; Capdepont M; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2013 May; 37(10):998-1004. PubMed ID: 23521659
[TBL] [Abstract][Full Text] [Related]
33. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
34. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
[TBL] [Abstract][Full Text] [Related]
35. Duration of disease may predict response to infliximab in pediatric ulcerative colitis.
Mir SA; Nagy-Szakal D; Smith EO; Gilger MA; Kellermayer R
J Clin Gastroenterol; 2014 Mar; 48(3):248-52. PubMed ID: 24129407
[TBL] [Abstract][Full Text] [Related]
36. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience.
Teisner AS; Ainsworth MA; Brynskov J
Scand J Gastroenterol; 2010 Dec; 45(12):1457-63. PubMed ID: 20701434
[TBL] [Abstract][Full Text] [Related]
37. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
